Prevention in Recipients With Primary IgA Nephropathy of Recurrence After

Status Terminated

Clinical Trial Summary

IgA nephropathy (IgAN) is a histologically defined glomerulonephritis (renal biopsy) by the presence of deposits immunoglobulin A (IgA) in the renal mesangium (at least 1+) by immunofluorescence. The clinic allows excluding secondary forms (10-15%). Recurrence of this condition on the renal graft is time-dependent and confirmed in 25 to 50% of 10 years post-transplant. The primary immunosuppressive induction regimens currently used in kidney transplantation are the anti-lymphocyte globulin (GAL) whose main target is human T lymphocytes (ATG, polyclonal) and monoclonal anti-CD25 antibodies (α chain of the interleukin receptor 2 in the surface of T lymphocytes). Due to their potent and prolonged immunosuppressive properties, the ATG may prevent or delay the recurrence on renal transplant. The aim of this study was to evaluate the influence of induction therapy (ATG versus Basiliximab) in the cumulative incidence at 5 years of (IgAN) recurrence after a first kidney transplant. This is a prospective, multicenter, randomized, open trial with a follow-up period of 5 years old. Patients in the ATG arm will receive 5 antilymphocyte globulin infusions Fresenius® (rabbit immunoglobulin antilymphocyte human T-Fresenius® said ATG) from Day 0 to Day + 4 post-transplant (day 0 one dose of 4mg / kg, day 1 one dose of 4mg/kg, day2 one dose of 4mgkg, day 3 one dose of 3 m/kg and day 4 and one final dose of 3 mg/kg) and the patients in the anti-CD25 arm will receive 2 doses of 20 mg of basiliximab (Simulect®) pn day 0 and day 4 after the graft. The maintenance immunosuppressive therapy is left to the discretion of the center. The primary endpoint will be the clinical and histological recurrence of IgAN defined by the presence of mesangial deposits of IgA (at least 1) by immunofluorescence on a biopsy of the graft triggered by the onset of proteinuria 1g/j and/or microalbuminuria greater than 300 mg / day.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02523768
Study type	Interventional
Source	Centre Hospitalier Universitaire de Saint Etienne
Contact
Status	Terminated
Phase	Phase 4
Start date	January 8, 2011
Completion date	February 24, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00001457` - Lamivudine for Chronic Hepatitis B	Phase 2
Recruiting	`NCT05505955` - Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency	Phase 1
Recruiting	`NCT01240564` - The Nephrotic Syndrome Study Network (NEPTUNE)	N/A
Active, not recruiting	`NCT05174221` - A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy	Phase 1
Completed	`NCT00426348` - A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy	Phase 4
Recruiting	`NCT04662723` - Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.	Phase 4
Completed	`NCT02700516` - Recurrent Glomerulonephritis After Renal Transplantation	N/A
Recruiting	`NCT00862693` - Calcitriol in the Treatment of Immunoglobulin A Nephropathy	Phase 4
Completed	`NCT00983034` - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy	N/A
Completed	`NCT00004990` - Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis	Phase 2
Recruiting	`NCT04846010` - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2	Phase 1/Phase 2
Terminated	`NCT04387448` - A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease	Phase 2
Terminated	`NCT04950114` - An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases	Phase 2
Completed	`NCT00437463` - Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor	Phase 3
Completed	`NCT00106561` - Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney	Phase 2/Phase 3
Completed	`NCT04733040` - Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)	Phase 2
Completed	`NCT00001676` - Cyclophosphamide and Fludarabine to Treat Lupus Nephritis	Phase 1
Recruiting	`NCT02063100` - Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis	Phase 4
Completed	`NCT01093157` - A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy	Phase 1/Phase 2
Completed	`NCT05283057` - Empagliflozin in Patients With Glomerulonephritis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment — PIRAT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms